A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia

BACKGROUND: Hetrombopag, a novel thrombopoietin receptor agonist, has been found in phase I studies to increase platelet counts and reduce bleeding risks in adults with immune thrombocytopenia (ITP). This phase III study aimed to evaluate the efficacy and safety of hetrombopag in ITP patients. METHO...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Hematol Oncol
Hauptverfasser: Mei, Heng, Liu, Xiaofan, Li, Yan, Zhou, Hu, Feng, Ying, Gao, Guangxun, Cheng, Peng, Huang, Ruibin, Yang, Linhua, Hu, Jianda, Hou, Ming, Yao, Yazhou, Liu, Li, Wang, Yi, Wu, Depei, Zhang, Liansheng, Zheng, Changcheng, Shen, Xuliang, Hu, Qi, Liu, Jing, Jin, Jie, Luo, Jianmin, Zeng, Yun, Gao, Sujun, Zhang, Xiaohui, Zhou, Xin, Shi, Qingzhi, Xia, Ruixiang, Xie, Xiaobao, Jiang, Zhongxing, Gao, Li, Bai, Yuansong, Xiong, Junye, Li, Runzi, Zou, Jianjun, Niu, Ting, Yang, Renchi, Hu, Yu
Format: Artigo
Sprache:Inglês
Veröffentlicht: BioMed Central 2021
Schlagworte:
Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7905908/
https://ncbi.nlm.nih.gov/pubmed/33632264
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-021-01047-9
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge